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Abstract
Bone marrow-derived human mesenchymal stem cells (hMSCs) have shown promise in in vitro neuronal differentiation and
in cellular therapy for neurodegenerative disorders, including Parkinson’ disease. However, the effects of intracerebral
transplantation are not well defined, and studies do not agreed on the optimal neuronal differentiation method. Here, we
investigated three growth factor-based neuronal differentiation procedures (using FGF-2/EGF/PDGF/SHH/FGF-8/GDNF), and
found all to be capable of eliciting an immature neural phenotype, in terms of cell morphology and gene/protein
expression. The neuronal-priming (FGF-2/EGF) method induced neurosphere-like formation and the highest NES and NR4A2
expression by hMSCs. Transplantation of undifferentiated and neuronal-primed hMSCs into the striatum and substantia
nigra of 6-OHDA-lesioned hemiparkinsonian rats revealed transient graft survival of 7 days, despite the reported
immunosuppressive properties of MSCs and cyclosporine-immunosuppression of rats. Neither differentiation of hMSCs nor
induction of host neurogenesis was observed at injection sites, and hMSCs continued producing mesodermal fibronectin.
Strategies for improving engraftment and differentiation post-transplantation, such as prior in vitro neuronal-priming, nigral
and striatal grafting, and co-transplantation of olfactory ensheathing cells that promote neural regeneration, were unable to
provide advantages. Innate inflammatory responses (Iba-1-positive microglia/macrophage and GFAP-positive astrocyte
activation and accumulation) were detected around grafts within 7 days. Our findings indicate that growth factor-based
methods allow hMSC differentiation toward immature neuronal-like cells, and contrary to previous reports, only transient
survival and engraftment of hMSCs occurs following transplantation in immunosuppressed hemiparkinsonian rats. In
addition, suppression of host innate inflammatory responses may be a key factor for improving hMSC survival and
engraftment.
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Introduction
Cellular transplantation is thought to hold great potential for the
treatment of Parkinson’ disease, since dopaminergic neurons are
selectively lost from the substantia nigra(SN) [1,2]. In the search for a
renewable source of dopamine-producing cells, human fetal brain
tissue [3,4], embryonic stem cells (SCs) [5–8], and neural SCs/
progenitors [9–11] have been investigated. Animal studies have
yielded encouraging findings including graft survival, dopamine
production and alleviation of motor deficits. Furthermore, recent
clinical trials examining human fetal mesencephalic tissue transplan-
tation into Parkinson’ disease patients have proven more optimistic
than in the past, with most transplants displaying functional activity
for at least a decade [12–14].
Neuronal differentiation of mesenchymal stem cells (MSCs; also
marrow stromal cells) has been achieved through a wide range of
approaches involving growth factors/signaling molecules, chemicals,
or a combination of both [15–25]. The validity of in vitro MSC
neuronal differentiation, particularly with chemical-based methods,
has recently been shrouded in controversy, with findings that the
rapid effects caused by chemical exposure resulted from culture
artifacts due to cellular toxicity, cell shrinkage and actin cytoskeleton
disruption [21,26,27]. Nevertheless, growth factor-based neural
differentiation has yielded promising results, with an earlier study
by our group demonstrating active and dynamic responses to growth
factor-induction, including the outgrowth and motility of cellular
extensions [28], whilst others have also shown the acquisition of
functional properties [29–32].
A number of studies have examined the ability of MSCs to
differentiate into dopamine-producing cells, re-innervate the
striatum, and ameliorate behavioral deficits in Parkinsonian
models. Varying degrees of success have been achieved in vitro,
including dopaminergic marker expression, electrophysiological-
activity, and/or dopamine secretion in response to depolarization
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provement were demonstrated following transplantation of
undifferentiated [36,37] and differentiated MSCs [33,35] in
hemiparkinsonian rodents. However, only relatively low efficien-
cies of dopaminergic differentiation (11%–41%) were achieved,
and comparisons between the varying methods have not been
performed, resulting in difficulties with identifying the optimal
methodology.
Olfactory ensheathing cells (OECs) have been shown to possess
unique properties advantageous for autologous transplantation in
the nervous system [38–42]. OECs are easily obtained through
nasal olfactory mucosa biopsy [43–45], and transplantation of
OECs promotes axonal regeneration and behavioral recovery in
spinal cord injury models [46,47]. In addition, co-transplantation
with fetal ventral mesencephalic cells in hemiparkinsonian rats
resulted in significant restoration of amphetamine-induced rota-
tional behavior, dopamine levels, and tyrosine hydroxylase (TH)
immunoreactivity [48,49]. Given the success of OEC transplan-
tation in neurological disease models, co-transplantation of OECs
may be beneficial for the engraftment and differentiation of MSCs
in neurological environments.
At present, a range of approaches have been implemented in
examining MSC dopaminergic differentiation and transplantation
in Parkinsonian models. Conflicting results have been obtained
and studies are not agreed on the optimal methodology. As a
result, pertinent issues remain to be resolved, including the optimal
method for inducing a dopaminergic phenotype from MSCs,
engraftment and survival capabilities of MSCs, optimal sites for
transplantation, potential immunological responses to MSC grafts,
and whether differentiation prior to transplantation provides
engraftment advantages. We addressed these issues by, firstly,
examining the generation of dopaminergic neuronal-like cells from
hMSCs through comparing three growth factor-based in vitro
methods, including a single-stage neuronal differentiation (Sin-
gleND) procedure [21], a recently published single-stage dopami-
nergic neuronal differentiation (SingleDA) method [32], and a
multiple-stage dopaminergic neuronal differentiation (MultiDA)
method that involves sequential stimulation with growth factors
important in midbrain dopaminergic neuron development.
Secondly, undifferentiated and neuronal-primed hMSCs were
transplanted into immunosuppressed hemiparkinsonian rats to
investigate graft survival and differentiation. Cells were injected
into the striatum, as this is the region requiring dopamine
provision and the site most commonly targeted in cellular
therapies for Parkinson’ disease. We also injected hMSCs into
the SN, since midbrain dopaminergic neurons develop in this
region. Thirdly, OECs were co-transplanted to evaluate whether
advantages or synergistic effects could be provided. The
neurotrophic and immunomodulatory effects of hMSCs on host
cells were also examined, since these mechanisms may play a role
in MSC-mediated improvement or restoration of neural deficits.
Materials and Methods
Ethics Statement
All research involving human participants was performed with
approval by the Human Research Ethics Committee of our
Institutes (St Vincent’ Hospital Sydney, Griffith University, and
Brisbane Private Hospital), and with written informed consent
obtained.
Animal studies were performed under approval from the
Animal Ethics Committee of Griffith University (GU Ref No:
SCE/06/05/AEC), and in strict accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes. All surgery was performed under anesthesia, and all
efforts were made to minimize suffering. Animals were housed in
pairs with 12-hour light/dark cycle and food/water ad libitum.
Isolation and Expansion of hMSCs
Bone marrow (1–2 mL) was collected into sodium heparin tubes
from the posterior iliac crest of hematologically normal donors,
and hMSCs were isolated as described [28], using RosetteSep
tetrameric antibody-mediated negative selection, density gradient
centrifugation, and plastic-adherence. Cells were cultured in
expansion medium (adapted from [50–52]): 60% DMEM-Low
Glucose (Gibco Invitrogen, CA, USA), 40% MCDB-201 medium,
1x insulin-transferrin-selenium, 1x linoleic-acid bovine serum
albumin, 10
29 M dexamethasone, 10
24 M ascorbic acid 2-
phosphate (AAP; Sigma-Aldrich, MO, USA), 100 U/mL penicil-
lin, 100 mg/mL streptomycin (Gibco) and 10% heat-inactivated
fetal bovine serum (Thermo Trace) at 37uC, 5% CO2 and 20%
O2. Cells were subcultured weekly with 0.05% trypsin/0.53 mM
EDTA (Gibco), thoroughly washed and re-plated at 2610
3 cells/
cm
2. Population doubling and cell viability were recorded at each
passage (P). Flow cytometric analysis and mesodermal differenti-
ation assays were performed, as described [28].
Neuronal Lineage Differentiation
Human MSC cultures in exponential growth phase (P4–6) were
exposed to three neuronal differentiation procedures (n=3). For
SingleND and MultiDA methods: growth factors were replenished
daily; medium changed every 2-days; cells were subcultured
weekly (trypsin/EDTA for 2-min) and harvested for characteriza-
tion at 1-, 2- and 3-weeks. Figure 1A summarizes these methods.
Single-Stage Neuronal Differentiation (SingleND). The
SingleND method was performed as reported [21]. Briefly,
hMSCs were plated at 6.7610
3 cells/cm
2 in fibronectin-coated
(Gibco) cultureware (Falcon/Becton Dickinson Labware, NJ,
USA) in medium containing DMEM/nutrient mixture F12, 1x
N-2 supplement, penicillin/streptomycin (all from Gibco),
supplemented with 10 ng/mL Fibroblast Growth Factor (FGF)-
2, 10 ng/mL Epidermal Growth Factor (EGF) and 1 ng/mL
Platelet-Derived Growth Factor (PDGF)(R&D Systems, MN,
USA).
Multiple-Stage Dopaminergic Neuronal Differentiation
(MultiDA). Cultureware was pre-coated with 2 m/cm
2 Poly-L-
ornithine (Sigma-Aldrich) and 1 mg/cm
2 Mouse Laminin (BD
Biosciences, MA, USA), and hMSCs seeded at 6.0610
3 cells/cm
2
in differentiation medium containing DMEM/nutrient mixture
F12 (without HEPES), 1x N-2 supplement, and penicillin/
streptomycin. Stage-1 medium was supplemented with 10 ng/
mL FGF-2 and 10 ng/mL EGF, to prime hMSCs towards a
neural fate. Stage-2 medium contained 100 ng/mL Sonic
Hedgehog (SHH) (R&D Systems), 10 ng/mL FGF-8 (human)
(PeproTech, Inc, NJ, USA) and 200 mM AAP, for initiating
midbrain specification. Stage-3 medium contained 50 ng/mL
Glial-Derived Neurotrophic Factor (GDNF) (R&D Systems) and
200 mM AAP, for inducing differentiation and maturation towards
a dopaminergic neuronal phenotype. Each stage was applied for 1-
week, and different combinations of stages were examined.
Single-Stage Dopaminergic Neuronal Differentiation
(SingleDA). The SingleDA method was performed as recently
reported [32]. Briefly, hMSCs were seeded into 6-well plates
(1610
5 cells/plate) with MSC expansion medium. After 1-day,
expansion medium was replaced with Neurobasal medium (Gibco),
0.25x B-27 supplement (Gibco), 250 ng/mL SHH, 100 ng/mL FGF-
8 (mouse) (R&D Systems), and 50 ng/mL FGF-2. Cells were harvested
after 6- and 12-days. Media was not replaced during this period.
Neuronal Differentiation & Transplantation of hMSC
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OECs were obtained frozen from the cell bank of the National
Centre for Adult Stem Cell Research (Griffith University). OECs were
generated from olfactory mucosa biopsies of human volunteers, in
accordance with published procedures [43]. OECs were genetically
labeled to express recombinant Green Fluorescent Protein (hrGFP), by
transduction with pFB-hrGFP retroviral supernatant (Stratagene),
according to manufacturer’ instructions. OECs were FACS-sorted to
isolate a population of .99% hrGFP-expressing cells, and maintained
in DMEM/HAM F12 medium (Gibco) containing 10% fetal calf
serum and penicillin/streptomycin. Details of the phenotype of these
cells are published [53].
RNA Extraction and Real-Time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen) and
RNeasy micro kit with DNase I treatment (Qiagen, Basel,
Switzerland). Total RNA (1 mg) was reverse transcribed with
Superscript III (Invitrogen) using 25 ng random hexamers and
1.25 mM Oligo(dT)20 primers, according to manufacturer’ recom-
mendations, and with RNase H treatment. Real-time RT-PCR
was performed using Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen) on a Rotor-Gene RG3000 machine (Corbett
Research, NSW, Australia). Further details are available online in
Materials and Methods S1 and Table S1.
Stereotactic Intracerebral Transplantation
Adult male 6-OHDA unilaterally-lesioned (SN pars compacta)
Wistar Ob rats (250-350 g) were obtained from the Integrative
Neuroscience Facility (Howard Florey Institute, VIC, Australia).
Rats were determined to have greater than 80% loss of SN pars
compacta neurons by amphetamine-induced rotational testing.
Undifferentiated hMSCs (P6) and neuronal-primed hMSCs
(MultiDA Stage-1) were harvested by trypsinization, washed twice,
and resuspended in Hank’ Balanced Salt Solution (HBSS; Sigma-
Aldrich) at 3610
4 cells/mL and 5610
4 cells/mL, respectively. A
total of 9610
4 undifferentiated hMSCs (3 mL) were injected into
Figure 1. Growth factor-induced neuronal differentiation of hMSCs. (A) Diagram of multiple-stage dopaminergic neuronal differentiation
(MultiDA), single-stage neuronal differentiation (SingleND), and single-step dopaminergic neuronal differentiation (SingleDA) [32] methods. (B)
Morphology of hMSCs during the MultiDA procedure. Images were captured at the end of each stage (1-week) of sequential growth factor treatment.
Representative phase-contrast images depicting hMSCs: prior to treatment (Ctrl; d0); after S1 (d7), S2 (d14), S2# (d14), S3 (d21), S3# (d21), and
S3(2#) (d21; S1 growth factors removed after S2) of differentiation (n=3). (C) Morphology of hMSCs during the SingleND procedure. Representative
phase-contrast images of hMSCs after: p1 (1 week), p2 (2 weeks), and p3 (3 weeks) (n=3). (D) Morphology of hMSCs during the SingleDA procedure.
Representative phase-contrast images of hMSCs: prior to treatment (Ctrl; d0), and d6 and d12 post-treatment (n=3). Ctrl, control undifferentiated
hMSCs; S, stage; #, growth factors from S1 included; ND, neuronal differentiation; p, passage; d, day. Scale bar: 100 mm.
doi:10.1371/journal.pone.0019025.g001
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5
neuronal-primed hMSCs (2 mL/site) were injected into the
lesioned striatum and SN (n=3; harvest at 1-, 7- and 21-days).
OECs were harvested similarly and resuspended in HBSS at
2.5610
4 cells/mL, together with neuronal-primed hMSCs (total of
5610
4 OECs/site).
For stereotactic transplantation, rats were anesthetized with
isofluorane gas (Affane, Bomac, NSW, Australia), and placed in a
stereotaxic frame with microinjector unit (Kopf Instruments, CA,
USA). Cell suspensions were injected into the lesioned hemisphere
with a 27-gauge needle fitted to a Hamilton syringe (Hamilton
Company, NV, USA) at co-ordinates: striatum (AP:1.2, L:-2.5,
V:5.0), SN (AP:-5.2, L:-3.2, V:-7.4). A cavity was created for the
injection through overshooting by 200 mm. After waiting 2-min
the cell suspension was injected at 1 mL/min. The needle was left
in place for 2-min and slowly withdrawn. Sham-operated animals
were infused with HBSS alone. All animals were immunosup-
pressed with daily cyclosporine A (10 mg/kg; subcutaneous;
Sandimmune, Sandoz Pharmaceutical, NJ, USA; similar to [8])
from 3-days prior to grafting until harvest.
Tissue Processing
Tissue was harvested following transcardial perfusion with
phosphate buffered saline followed by Zamboni’ Fixative, and
processed with further fixation and embedding in polyethylene
glycol. Sectioning was performed at room temperature on a rotary
microtome to obtain 30 mm thick sections. See online Materials
and Methods S1 for further details.
Immunofluorescence Staining and Analysis
For details see online Materials and Methods S1. Primary
antibodies included: mouse monoclonal antibodies (all IgG)
against nestin (NES), microtubule-associated protein-2 (MAP-2),
neuronal nuclear antigen (NeuN), TH, Glial Fibrillary Acidic
Protein (GFAP)-Cy3, and Human Nuclear Antigen (HuNuc; clone
235-1); and rabbit polyclonal antibodies against Fibronectin,
GFAP, b-tubulin III, and Iba-1. Alexa Fluor 488 or 594 highly-
cross-adsorbed goat anti-rabbit or anti-mouse secondary antibod-
ies were used. Negative controls consisted of secondary antibody
application alone (in vitro). Contralateral brain regions served as
internal controls (in vivo). Confocal imaging was performed using a
Leica laser-scanning confocal microscope (DM IRE2 TCS SP2
AOBS; Leica Microsystems, Wetzlar, Germany). Individual color
channels were captured separately and merged in Adobe Photo-
shop. Co-localization of HuNuc and DAPI signals were confirmed
through analyzing z-series confocal reconstructions and corre-
sponding orthogonal planes under 40x and 100x. Contralateral
brain regions served as internal controls to confirm primary
antibody specificity. Images presented are ‘aximum projection
images’ from z-stacks, with 10 images captured over the thickness
of the section (30–45 mm).
Statistical Analysis
Gene expression data were expressed as mean fold-change in
mRNA expression + SEM relative to control undifferentiated
hMSCs. The student’ t-test was performed to determine significant
differences (p,0.05) using Microsoft Excel.
Results
In Vitro Dopaminergic Neuronal Differentiation of hMSCs
Induces Neuronal-like Morphology
Prior to differentiation hMSCs possessed a fibroblast-like
appearance (Ctrl in Fig. 1B and D), and exhibited standard
MSC properties, as previously reported [28]. The three growth
factor-based treatments produced cells with similar neuronal-like
bipolar or multipolar morphology, with formation of refractile cell
bodies and long thin processes, occasionally containing branching
or minute protuberances (Fig. 1B-D). These changes occurred
gradually over the differentiation period. Treatment with the
MultiDA protocol yielded the most distinct morphological
alterations (Fig. 1B). Following stage (S) 1, hMSCs developed a
bipolar, refractile appearance and formed neurosphere-like
clusters. Subsequently, in S2 and S3 many cells returned to a
flatter appearance. Adding S1 growth factors to later stages (#)
maintained the bipolar refractile morphology, however, uninter-
rupted treatment with S1 growth factors resulted in less complex
branching. A considerable decrease in cell number was also
observed with each stage (trypan blue cell count; data not shown).
Application of the recently reported SingleDA method [32]
generated a neuronal-like morphology similar to published results
(Fig. 1D), which also resembled SingleND-treated cells (Fig. 1C;
[21]); however, neither resulted in neurosphere-like formation.
SingleND also elicited reduced cell numbers, while SingleDA
yielded slight increases (data not shown).
Increased Neural Gene Expression After In Vitro hMSC
Neuronal Differentiation
Expression of neuronal, dopaminergic neuronal, glial, meso-
dermal, and pluripotency genes were examined (Fig. 2 and Fig. 3).
Neuronal progenitor marker NES, and neuronal markers, MAP-2
and neuron-specific enolase (ENO2), were detected in all samples
before and after differentiation. NES was significantly up-regulated
in all conditions, apart from MultiDA S2. The MultiDA procedure
induced the highest levels of NES, and addition of S1 growth
factors appeared beneficial for NES expression. Human MSCs also
expressed nuclear receptor subfamily 4, group A, member 2
(NR4A2; also Nurr1; transcription factor essential for midbrain
dopaminergic differentiation) and TH (rate-limiting enzyme in
catecholamine synthesis) prior to and following induction. A trend
of increasing NR4A2 expression could be observed in MultiDA S1
and S2#. Both single-step methods resulted in decreasing NR4A2
expression. The highest levels of TH expression were observed
with SingleND. Glial gene GFAP was significantly up-regulated in
MultiDA S1 and S2#, but was not significantly changed in all
other conditions. Expected down-regulation of mesodermal
marker collagen I (COL1A1) was not observed with any method,
and instead, COL1A1 was significantly increased in MultiDA
without FGF-2/EGF. Only weak expression of pluripotency
markers POU class 5 homeobox 1 (POU5F1; also OCT3/4) and
Nanog homeobox (NANOG) were detected.
Increased Expression of Early Neuronal Proteins After
In Vitro hMSC Neuronal Differentiation
PCR findings were confirmed by immunofluorescence staining
for protein expression (Fig. 4 and Fig. 5). Consistent with PCR,
NES was detected in both undifferentiated control hMSCs (,10%
positive) and at all time points examined during neuronal
differentiation (,20% positive). NES protein occurred in a
cytoskeletal pattern, and appeared slightly up-regulated following
all differentiation methods examined. The percentage of positive-
ly-stained cells may be underestimated due to the loss of neuronal-
like cells during slide processing, since these cells were loosely
attached to culture surfaces. Prior to differentiation, some hMSCs
expressed low levels of b-tubulin III (,15%). Following differen-
tiation, .80% of cells exhibited cytoskeletal b-tubulin III staining,
except in SingleND (.90% positive) and MultiDA S2 and S3
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tin was strongly expressed by undifferentiated hMSCs (90–100%)
in an extracellular fibrous pattern. Continued fibronectin
expression was detected following differentiation (.90%), except
in MultiDA S3, which showed slightly lower proportions (.80%)
of fibronectin expression and weaker staining intensity. Other
markers examined (GFAP, NeuN and TH) were absent from the
majority of cells and weak expression could only be detected
occasionally (not shown).
Limited Survival of hMSCs and OECs Post-Transplantation
To identify transplanted human cells, graft regions were
examined by HuNuc staining, and GFP fluorescence for OEC
identification (Fig. 6). Cells displaying co-localization of HuNuc
and DAPI were found within striatal and nigral graft sites at 1-day
post-transplantation (Fig. 6A and G). Surviving hMSCs were
visible as a mass of cells toward the end of the needle tract, with
few at the needle entry point (Fig. 6F), and none in the
contralateral hemisphere (Fig. 6E). Over time HuNuc staining
decreased, with little signal remaining at 7-days (Fig. 6B and H),
and complete absence by 21-days (Fig. 6C and I). In addition,
autofluorescent cell debris and lipofuscin-like material were found
within graft cores, which increased in parallel with HuNuc loss,
and reduced graft size and cellular density. No difference was
observed between grafts containing neuronal-primed hMSCs
alone or in combination with OECs. Concomitant loss of the
OEC-derived GFP signal provides further support for the transient
in vivo survival of human cells. Analysis of undifferentiated hMSC
grafts at 2-months post-transplantation also revealed absence of
engraftment, with graft cores also containing autofluorescent
debris (results not shown). Confocal z-series analysis showed co-
localization of HuNuc signals with DAPI-stained nuclei (arrows)
for both hMSC only and OEC co-transplanted grafts at 1-day
post-transplantation (Fig. 6J), excluding possible misinterpretation
due to overlaying fluorescent signals.
Accumulation of Astrocytes and Microglia/Macrophages
at Graft Sites
To investigate the loss of hMSCs and OECs, graft sites were
characterized for the presence of glia. Striatal and nigral grafts
displayed massive infiltration by Iba-1-positive microglia/mac-
rophages and GFAP-positive astrocytes, which increased over
Figure 2. Increased neural gene expression in hMSC cultures undergoing in vitro neuronal and dopaminergic neuronal
differentiation. Real-time RT-PCR results from the MultiDA (purple shades), SingleND (blue shades), and SingleDA (orange shades) [32] methods.
Neuronal genes: NES, MAP-2 and ENO2. Dopaminergic neuronal genes: NR4A2 and TH. Mesodermal gene: COL1A1. Results are depicted as mean fold
change in mRNA expression + SEM relative to control undifferentiated hMSC cultures, with baseline set at 1.0 (n=3). * p,0.05 compared with the
control, unless indicated by brackets. Ctrl, control undifferentiated hMSCs; S, stage; #, growth factors from S1 included; P, passage; d, day.
doi:10.1371/journal.pone.0019025.g002
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phages were present in a radial pattern around the graft core.
Increased astrocytic presence was also found surrounding the
graft site and extending beyond the microglia/macrophage
layer. Undifferentiated hMSC grafts examined at 2-months also
showed evidence of astrocytic infiltration and/or proliferation at
graft sites and along needle tracts (data not shown). Furthermore,
these microglia/macrophages displayed an activated appear-
ance, with intense Iba-1 staining [54], and altered morphology
including retraction and thickening of processes and increased
cytoplasmic area [54,55].
Corresponding regions in the contralateral hemisphere did not
exhibit glial accumulation (Fig. 7D-F), and microglia possessed
quiescent morphology (small cell bodies and fine cytoplasmic
ramifications). Interestingly, sham controls showed some evidence
of glial accumulation, suggesting that this may be a response to
injury caused by needle insertion (data not shown).
Absence of Endogenous Host Neuronal Differentiation
Post-Transplantation
Graft regions were examined for host neuronal progenitor
activity because hMSC transplantation has been proposed to elicit
host responses that may account for functional improvement.
Immunohistological analysis for NES (Fig. 8A–D) revealed little, if
any, NES immunoreactivity at any period. Host cells that
expressed NES were predominantly GFAP-positive astrocytes
immediately surrounding grafted cells, indicating activation [56].
A few rare NES-positive cells could be detected within the graft
core and at astrocytic borders at 7-days (Fig. 8D). The location of
the NES-positive cells suggests that this staining is unlikely to
represent host neuronal progenitor involvement. Instead, NES
expression may originate from neuronal-primed hMSCs that
express NES gene and protein, and is consistent with absence of
NES at 21-days. No differences were observed between striatal
and nigral grafts of neuronal-primed hMSCs alone or with OECs.
Lack of Neuronal Marker Expression by Transplanted
hMSCs at Graft Sites
Since NES was detected in a small proportion of cells within the
graft, further characterization for neuronal markers was conduct-
ed. Neuronal b-tubulin III immunoreactivity was not observed in
the transplantation region (Fig. 8E–G), whereas the contralateral
region showed consistent evenly distributed expression (Fig. 8H),
suggesting that surgical trauma caused loss of host b-tubulin III.
Similar results were observed with OEC co-transplantation.
Staining for TH confirmed strong unilateral expression within
varicose nerve fibres in the unlesioned hemisphere (Fig. 9D–F),
with a complete absence of TH-localizing nerve fibres within the
striatum of the lesioned hemisphere. TH staining was predomi-
nantly absent from graft sites (Fig. 9A–C), regardless of the
transplantation site or whether OECs were co-transplanted.
Sham-treated animals also did not exhibit TH expression at
injection sites (Fig. 9H and I).
Extracellular Matrix Deposition at Graft Sites
A dense fibronectin-positive matrix was observed surrounding
neuronal-primed hMSC grafts as early as 1-day post-transplanta-
tion, and decreased over time with little remaining at 21-days
(Fig. 9A–C). Similar findings were obtained with co-transplanta-
tion of OECs at both striatal and nigral sites (not shown); while
only slight fibronectin expression was detected contralaterally
(Fig. 9D–F). Sham controls displayed very little, if any, fibronectin
deposition (Fig. 9G–I). This suggests that the dense fibronectin
matrix was produced by the transplanted human cells, rather than
being deposited by host cells during scar formation. Fibronectin
decreased considerably in parallel with hMSC and OEC loss,
Figure 3. Increased neural gene expression in hMSC cultures undergoing in vitro neuronal and dopaminergic neuronal
differentiation. Real-time RT-PCR results from the MultiDA (purple shades), SingleND (blue shades), and SingleDA (orange shades) [32] methods.
Glial genes: GFAP and CSPG4. Pluripotency genes: POU5F1 and NANOG. Results are depicted as mean fold change in mRNA expression + SEM relative
to control undifferentiated hMSC cultures, with baseline set at 1.0 (n=3). * p,0.05 compared with the control, unless indicated by brackets. Ctrl,
control undifferentiated hMSCs; S, stage; #, growth factors from S1 included; P, passage; d, day.
doi:10.1371/journal.pone.0019025.g003
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differentiation. Representative images depicting immunofluorescence staining of control undifferentiated hMSC cultures and cultures treated
with the MultiDA procedure (n=3). Cells were examined for expression of neuronal progenitor marker NES, astroglial marker GFAP, neuronal markers
NeuN and b-tubulin III, dopaminergic neuronal marker TH, and mesodermal marker fibronectin. Growth factor-treated cells were observed to express
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is also supported by continued expression of fibronectin protein by
neuronal-primed hMSCs in vitro (Fig. 4 and Fig. 5).
Discussion
In this report we have shown that: 1) treatment of hMSCs with
three growth factor-based neuronal differentiation procedures
elicited similar immature neuronal-like phenotypes, with continual
FGF-2/EGF supplementation achieving neurosphere-like forma-
tion and the highest expression of NES and NR4A2; 2) hMSCs
survived transiently in the lesioned hemisphere of immunosup-
pressed Parkinsonian rats; 3) activated astrocytes and microglia/
macrophages accumulated around graft sites, indicating the
presence of an inflammatory response; 4) further differentiation
of neuronal-primed hMSCs was not observed in vivo, and
neuronal-primed hMSCs continued producing fibronectin matrix;
5) hMSC-derived neurotrophic effects on host neuronal progen-
itors/cells were not apparent in complete-lesion Parkinsonian
rodents; and 6) co-transplantation of OECs did not enhance graft
survival or differentiation.
Previously, we showed that application of growth factors and
neural-inducing culture conditions resulted in immature neuronal-
like differentiation of hMSCs [21,28]. In the present study, we
endeavored to induce a dopaminergic phenotype through
sequential application of growth factors important in midbrain
dopaminergic neuronal development. With a range of methods
reported and no consensus on an optimal method, we also
conducted a comparison of published methods. Despite the
different growth factors, surface coatings and culturing procedures
employed, all three methods examined only generated immature
neuronal-like cells. Nevertheless, MultiDA S1 yielded the greatest
increases in NES and NR4A2 expression, as well as neurosphere-
like formation and enhanced cell survival compared to S2 and S3,
and as a result was selected for in vivo experiments. Observations
that cultures were not maintained well in later stages of the
MultiDA system raises questions regarding the responsiveness of
hMSCs to SHH, FGF-8 and GDNF. Previous reports showed
these growth factors to be beneficial for in vitro MSC dopaminergic
neuronal differentiation [22,32,33,35]. In addition, MSCs are
known to functionally express both components of the SHH
receptor, as well as FGF receptors FGFR1 and FGFR4 [32,57];
however, only part of the GDNF receptor was expressed,
rendering MSCs incapable of responding to GDNF. This suggests
variability in MSC expression of growth factor receptors, and may
account for the inability of MultiDA S3 to elicit the expected
differentiation effects.
The stage of SC differentiation that is optimal for transplan-
tation purposes has not been well defined, although it is believed
that immature neuronal cells possess the greatest potential for
successful engraftment and integration into host circuitry [20,23].
The growth factor-based methods employed here were successful
in driving hMSCs towards an early neuronal fate; however, cells
continued expressing mesodermal and pluripotency markers,
suggesting that further neuronal differentiation may be required.
Future experiments are warranted for investigating whether the
electrophysiological properties of these neuronal-like cells resemble
that of immature neurons. The minimal expression of TH protein
suggests that dopamine is not produced, and additional agents or
cell-to-cell contact with neural support cells may be required for
generating dopamine-secreting cells. Another comparative study
also found continued expression of mesodermal marker fibronectin
after application of different neuronal differentiation methods
[58]. These findings highlight the importance of showing
concomitant down-regulation of mesodermal and MSC markers
with neuronal differentiation, which has not been commonly
examined. MSC neuronal differentiation could be improved by
addition of fatty acids, such as docosahexaenoic acid and
arachidonic acid [59], inflammatory mediator IL-1a [29,60],
and retinoic acid, Brain-Derived Neurotrophic Factor and/or
Nerve Growth Factor [32].
Transplantation of undifferentiated and neuronal-primed
hMSCs into the lesioned hemisphere of immunosuppressed
hemiparkinsonian rats yielded transient graft survival. A number
of factors may be responsible for this, including: the presence of
innate inflammatory responses that may have been initiated by
surgical trauma during transplantation; the xenogeneic nature of
the graft; and the ‘foreign’ nature of hMSCs, which had not gained
a mature neuronal phenotype as evidenced by continued
fibronectin production. It is also possible that the lesioned adult
rat striatum and SN may lack the appropriate factors for
supporting hMSC survival, engraftment and differentiation. These
findings contradict earlier reports [33,35,36,61–64], which have
demonstrated some level of MSC-induced repair in Parkinsonian
models; however, shows similarity with recent reports describing
limited MSC survival post-transplantation [23,65,66]. Initial
reports employed BrdU and other thymidine analogs for cell-
labelling, which have since been found to result in the transfer of
donor labels to host cells [65,67]. These cell-labelling techniques
may provide misleading indication of donor cell survival and
differentiation. In the present study, we avoided the use of these
labels and identified human cells by immunohistological detection
through human-specific antibodies and GFP-transgene fluores-
cence (OECs). Our findings of limited MSC survival are consistent
with these recent reports, and suggest that discrepancies with
earlier studies may be related to the varying methods of graft
detection.
The immunosuppressive effects of MSCs have primarily been
demonstrated in in vitro studies, and initially focused on T
lymphocyte effects [68–70]; however, the relevance to in vivo or
clinical settings remains unclear, although the limited data
available at present provides little evidence that donor MSCs are
able to engraft after infusion or transplantation [71,72]. Never-
theless, studies have reported the transplantation of allogeneic or
xenogeneic MSCs into the brain of immunocompetent animals
without detection of a host immune response [73–75]. We
detected the presence of microglial/macrophage accumulation
after hMSC transplantation into the lesioned hemiparkinsonian
rat brain. This inflammatory response occurred in the presence of
cyclosporine immunosuppression and was also present in sham
controls, indicating that while it was not specific to the
transplanted cells, the inflammatory response was not abolished
by hMSCs. Increasing evidence that MSCs may not be
intrinsically immune-privileged has been reported. An immediate
inflammatory response was elicited following allogeneic MSC
grafting in intact adult rat hippocampus or striatum [65]. In
addition, robust cellular immune responses were generated
following injection of MSCs into the striatum of allogeneic
NES, and up-regulated b-tubulin III expression, but other neural markers were not detected. Cells also continued to strongly express fibronectin.
These results suggest that the MultiDA method was only capable of generating immature neuronal-like cells. Nuclei were counterstained with DAPI.
Negative controls consisted of secondary antibody application alone (not shown). S, stage; #, growth factors from S1 included. Scale bar: 50 mm.
doi:10.1371/journal.pone.0019025.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19025Figure 5. Increased early neuronal protein expression by hMSCs during in vitro neuronal and dopaminergic neuronal
differentiation. Representative images depicting immunofluorescence staining of control undifferentiated hMSC cultures and cultures treated
with the SingleND and SingleDA procedures (n=3). Cells were examined for expression of neuronal progenitor marker NES, astroglial marker GFAP,
neuronal markers NeuN and b-tubulin III, dopaminergic neuronal marker TH, and mesodermal marker fibronectin. Growth factor-treated cells were
observed to express NES, and up-regulated b-tubulin III expression, but other neural markers were not detected. Cells also continued to strongly
express fibronectin. These results suggest that all 3 neuronal differentiation methods investigated were only capable of generating immature
neuronal-like cells. Nuclei were counterstained with DAPI. Negative controls consisted of secondary antibody application alone (not shown). P,
passage; d, day. Scale bar: 50 mm.
doi:10.1371/journal.pone.0019025.g005
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19025Figure 6. Evidence of limited survival of neuronal-primed hMSCs in the lesioned hemisphere of the hemiparkinsonian rat. The
survival and engraftment of neuronal-primed hMSCs and GFP-positive OECs (green) were examined by immunohistological staining using an
antibody against Human Nuclear Antigen (HuNuc; red). Representative images following transplantation of (A–F) neuronal-primed hMSCs alone, and
(G-I) co-transplanted with OECs (n=3; maximum projection z-stacks shown (35 mm)). Surviving human cells could be detected at 1-day post-
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to inhibit T lymphocyte-mediated immunity [76], indicating the
involvement of other arms of the immune system in MSC loss.
Other studies have also shown that cyclosporine treatment is
suboptimal for xenotransplantation of neural cells into neural
regions [77], and that complement factors, immunoglobulins and
macrophages are involved in responses against discordant
xenografts [78–80]. Whilst, transplantation of MSCs has been
performed without immunosuppression [35,73–75], or with
cyclosporine-based [23,61,64,81] or FK506-based [33] immuno-
suppression, our findings suggest that suppression of the innate
immune response may be required for improved graft survival.
Recently, enhanced microglial suppression was employed for
transplantation into degenerated retina through application of oral
cyclosporine A, azathioprine, prednisolone, and indomethacin,
which decreased microglial accumulation and increased SC
survival [82].
Following transplantation of hMSCs alone or with OECs, we were
unable to detect further signs of neuronal or dopaminergic neuronal
differentiation and maturation. In line with this and the lack of
engraftment, assessment of behavioural function in hemiparkinsonian
rats by amphetamine-induced rotational asymmetry showed no
improvementat1 month post-transplantation of hMSCs(not shown).
Coyne and colleagues also failed to observe maturation of
undifferentiated MSCs following intracerebral transplantation in
normal adult rats [65]. They attributed this to the limited capacity of
the intact adult brain for directing the differentiation of transplanted
SCs. We grafted hMSCs into the striatum, as this is the region
requiring dopamine provision, as well as the SN, since the cell bodies
of midbrain dopaminergic neurons are contained in the SN and
transplantation (A and G). However, by 7-days little HuNuc signal remained (B and H), and this could no longer be detected by 21-days (C and I).
Higher magnification view of (A) is shown in (D), with HuNuc staining seen to be co-localised with DAPI-stained nuclei (blue). Increasing presence of
autofluorescent matter (aqua) within the graft core was observed in parallel with the loss of human cells (arrows in B, C, and H). This autofluorescence
and HuNuc staining were not observed in the corresponding regions in the contralateral hemisphere (representative image shown in (E)). The
majority of human cells were concentrated in the needle tract with few, if any, detected at the needle entry site (F). Similar findings were observed in
both striatal and nigral graft sites. (J) Confocal z-series identification of human cells. Examination of z-series images from graft sites confirms co-
localisation of HuNuc (red) signal with DAPI-stained nuclei (blue) within the nigral graft site at 1-day (arrows). Similar results were obtained for striatal
graft sites and OEC co-transplanted animals, as well as at 7-days. Scale bar: 150 mm in (I) for (A–C, E–I); 30 mm for (D) and (J).
doi:10.1371/journal.pone.0019025.g006
Figure 7. Increasing glial accumulation at graft sites during the initial 3-weeks post-intracerebral transplantation in
hemiparkinsonian rats. Immunohistological analysis revealed the accumulation of GFAP-positive astrocytes (red) and Iba-1-positive microglia/
macrophages (green) at graft sites (n=3). Representative images depicting (A–C) neuronal-primed hMSC graft sites in the striatum, and (D–F)
corresponding region controls in the contralateral hemisphere, at 1-day (left column), 7-days (middle column) and 21-days (right column). (A) Initially,
at 1-day post-transplantation little GFAP or Iba-1 was detected. (B) By 7-days grafts were densely surrounded by a layer of GFAP-positive and Iba-1-
positive cells, and contained an autofluorescent core (white arrow). (C) At the end of the 21-day period a marked astrogliosis was present in the graft
region. Both striatal and nigral grafts exhibited this glial accumulation, which suggests the presence of an inflammatory response at graft sites. (D–F)
This pattern of glial distribution was absent from the contralateral hemisphere. Images shown are maximum projection z-stacks. Nuclei have been
counterstained with DAPI (blue). Scale bar: 150 mm.
doi:10.1371/journal.pone.0019025.g007
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PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e19025Figure 8. Absence of endogenous host neuronal differentiation and neuronal marker expression within neuronal-primed hMSC
graft sites. Striatal and nigral grafts were examined for the presence of NES (green) and GFAP (red) at (A) 1-day, (B) 7-days, and (C) 21-days post-
transplantation (n=3). (D) Higher magnification view of boxed area in (B). Rare NES-positive cells were only detected within the graft core or in the
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However, only transient graft survival was observed in both regions
in the absence of differentiation. Furthermore, fibronectin deposition
was only observed at hMSC graft sites, suggesting that the hMSCs
were the source of fibronectin, and therefore still possessed primitive
properties. These observations are in accordance with recent work
immediate astroglial boundary at 7-days. NES-positive activated astrocytes could also be detected. Graft sites were also examined for the presence of
b-tubulin III (green) and human nuclear antigen (HuNuc; red) at (E) 1-day, (F) 7-days, and (G) 21-days post-transplantation (n=3). Expression of b-
tubulin III was missing from the region containing the graft sites, and was primarily found surrounding the graft core; while, the corresponding
regions in the contralateral hemisphere (Opp Hem) exhibited evenly distributed b-tubulin III expression (representative image shown in (H), which is
contralateral to (E)). Similar results were observed in OEC co-transplanted recipients. Representative images shown are maximum projection z-stacks
(40 mm). Nuclei were counterstained with DAPI (blue). Scale bar: 150 mm in (C) for (A–C); 40 mm for (D); 150 mm in (H) for (E–H).
doi:10.1371/journal.pone.0019025.g008
Figure 9. Matrix deposition and lack of dopaminergic neuronal differentiation after transplanting neuronal-primed hMSCs and
OECs. Fibronectin and TH expression were assessed in striatal and nigral grafts at 1-day (left column), 7-days (middle column) and 21-days (right
column). Representative images are shown of (A-C) neuronal-primed hMSC graft sites in the striatum, (D–F) corresponding regions in the contralateral
hemisphere, and (G–I) injection sites in sham controls (n=3). Immunohistological analysis revealed a fibronectin-positive matrix surrounding hMSC
graft sites from 1-day post-transplantation (A and B), however, this was markedly reduced by 21-days (C). The concomitant loss of transplanted cells
suggests that the fibronectin matrix was deposited by the graft. Furthermore, sham injected animals did not exhibit dense fibronectin expression (G–
I). TH expression was not detected in any graft sites or sham-injected sites, and was only expressed in the unlesioned hemisphere (D–F). Similar
results were observed in OEC co-transplanted recipients. Images shown are maximum projection z-stacks. Nuclei were counterstained with DAPI
(blue). Scale bar: 150 mm.
doi:10.1371/journal.pone.0019025.g009
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derived committed neural precursor cells in a rat model of focal
cerebral ischemia, which demonstrated enhanced engraftment and
functional improvement with the more neurally-committed cells [83].
The mechanism by which MSCs exert functional improvements
in vivo has been the subject of recent controversy. Pioneering
studies suggested that tissue repair of different organ systems
occurred via the broad developmental plasticity and transdiffer-
entiation capacity of MSCs; our findings contribute to emerging
evidence that suggests MSCs exhibit low or transient levels of in
vivo engraftment and transdifferentiation, and may possess a more
prominent role in secreting factors that alter host microenviron-
ments [84]. Tissue repair may then occur through stimulation of
survival and proliferation of host cells, modulation of immune
responses, induction of angiogenesis, and reduction of apoptosis.
In the present study, the absence of a host regenerative response
may be related to the severe, complete-lesion hemiparkinsonian
model employed where there is no chance for rescuing damaged
neurons, since the process of neuronal death is complete. The
high-severity lesion used here may also explain why strategies of
OEC co-transplantation and nigral and striatal grafting could not
improve hMSC survival, differentiation and induction of host
regeneration. Recently, other studies have reported that co-
grafting of OECs with olfactory nerve fibroblasts and neural SC-
derived dopaminergic neurons is beneficial for dopaminergic axon
transection [85] and Parkinsonian rodents [86], respectively. A
supportive role for OECs was further suggested by findings that
OEC transplantation alone was insufficient for promoting tissue
repair and recovery in hemiparkinsonian rats [87]. Alternatively,
an MSC-induced protection-restoration effect on host neural cells
may be possible in a partial-lesion hemiparkinsonian model
containing residual surviving dopamine terminals. Promising
results of behavioral improvement have recently been obtained
with this type of model and transplantation of MSC-derived
neurotrophic factor-secreting cells [64].
Despite the issues raised above, the current state of research
suggests that MSC-based cellular therapies are possible for
neurological diseases and disorders, although are much more
complicated than initially believed with involvement of distinct
underlying mechanisms. Our findings highlight the need for
further careful studies to resolve the controversies and inconsis-
tencies within the field, and to allow the proper development of
reproducible and reliable methods for MSC application in cellular
therapies for neurological diseases. Key areas warranting further
investigation include the ‘supportive’ (neurotrophic) qualities of
MSCs and MSC-derived cells, and the effects of transplanting
these cells in partial- versus complete-lesion Parkinsonian models.
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